Lucid Ultra 128 vs Otofonix Encore
Side-by-side HearAdvisor lab results with SoundGrades, expert pick badges, and the same visualizations we use in product reviews.
Choice

Lucid Ultra 128
The Lucid Ultra 128 is a premium behind-the-ear prescription hearing aid priced at $5,000, earning an A grade with a SoundScore of 4.4/5 in our lab testing. It ranks #17 among 39 prescription hearing aids tested, placing it in the top 41% of its category. Speech performance is where the Lucid Ultra 128 truly excels. In our lab testing, speech in quiet scored a strong 4.3/5, which is 0.95 points above the category average. Speech in noise performance reached 2.7/5, which sits above the category average by 0.59 points, though it remains mixed in absolute terms. This suggests the device handles conversational clarity well in our test scenarios, particularly in quieter environments. The device does face some challenges. Feedback handling scored just 1.7/5, falling 3.02 points below the category average of 4.72/5—a notable weakness compared to other prescription aids in our testing. Music streaming also came in below average at 2.3/5, which is 0.46 points under the category norm. Own-voice comfort scored a mixed 2.9/5, slightly above average. At this price point, several competitors in our database achieved higher overall scores, including the Phonak Sphere Infinio and Oticon Intent. The Lucid Ultra 128 features disposable batteries and supports both iPhone and Android streaming. It may appeal to users who prioritize speech clarity in quiet settings and are less concerned about feedback stability or music streaming fidelity in our standardized tests.

Otofonix Encore
The Otofonix Encore is a budget-priced prescription hearing aid available for $295, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This behind-the-ear device ranks #37 of 39 in the Prescription Hearing Aid category, placing it in the bottom tier of its class. In our standardized testing, the Encore demonstrates one clear strength: excellent feedback handling at 4.7/5, which means users are unlikely to experience whistling or squealing during normal use. However, the device shows significant limitations in other areas. Speech intelligibility scores are low in both quiet (1.0/5) and noisy environments (1.0/5), falling 2.40 and 1.11 points below category averages respectively. Music streaming performance scored 0.0/5, indicating this device is not suitable for those who want to stream audio content. The Encore uses disposable batteries and comes in a traditional behind-the-ear style. Notably, our tuned fit testing showed a slight decrease in overall performance compared to the initial fit, with the normalized score dropping from 2.8/5 to 2.4/5. Own-voice comfort also declined substantially when moving to a more occluding coupling. At this price point, consumers may want to consider alternatives. The RxEars Rxi offers substantially better performance at a similar budget price point with a score of 4.07/5. The Otofonix Encore may appeal to buyers seeking a very low-cost entry into prescription hearing aids who prioritize feedback stability, but those needing reliable speech clarity or streaming capabilities should explore other options.
Performance metrics
Scale 1-5 (Tuned)
Lab metric by fit
Scale 1-5 (Tuned)
Speech level
Adjust input dB (Tuned)
Amplification (REIG)
Insertion gain at 65 dB (Tuned)
Audio scenes
Recorded samples (Tuned)
Fitting configuration for tuned fit